Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).
Completed · Phase 1 · Has a placebo group
Conditions studied: Electrical Status Epilepticus of Slow-Wave Sleep
In brief
This study aims to assess the efficacy of Epidiolex in patients with ESES. ESES is characterized by sleep potentiated spikes with a spike index greater than 85% (conventional definition) and 50% (new definition)1. Several drugs including: steroids, intravenous Gama globulin, Clobazam, other benzodiazepines, Valproic acid, and other anti-epileptic drugs have been tried with mixed benefits2,3. Cannabidiol (CBD) would provide a novel mechanism of action to assess for its efficacy in this population. This will be a double-blind placebo-controlled crossover clinical trial.
Key facts
- Study ID
- NCT04721691
- Run by
- Northwell Health
- People needed
- 16
- Starts
- 2021-03-10
- Expected to finish
- 2024-01-17
- Last updated by the study team
- 2025-06-04
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwell Health — Lake Success, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.